Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2007

01-07-2007 | Letter to the Editor

Epidermal Growth Factor Receptor and Prognosis in Colon Cancer: A Crack in the Wall?

Authors: Gerardo Ferrara, MD, Natalia Palombi, PhD, Arturo Di Blasi, MD

Published in: Annals of Surgical Oncology | Issue 7/2007

Login to get access

Excerpt

The immunohistochemical expression of the epidermal growth factor receptor (EGFR) on paraffin-embedded tissue samples has been increasingly studied in the last few years, mainly in colon cancer after the introduction of new targeted monoclonal antibodies in antitumor drug therapy.1 Because EGFR activation can promote cell proliferation and survival,2 it is not surprising that EGFR expression in colon cancer has been found to positively correlate with progression and metastatic potential.3‐7 …
Literature
1.
Nygren P, Sørbye H, Österlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol 2005; 44:203–17PubMedCrossRef
2.
Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signalling in establishment of adenomas and maintainance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A 2002; 99:1521–6PubMedCrossRef
3.
Tong W-M, Ellinger A, Sheinin Y, Cross HS. Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells. Br J Cancer 1998;77:1792–8PubMed
4.
Hayashi Y, Widjono YW, Ohta K, et al. Expression of EGF, EGR-receptor, p53, v-erbB and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. Pathol Int 1994; 44:124–30PubMedCrossRef
5.
Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1:19–31PubMed
6.
Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004; 10:3069–75PubMedCrossRef
7.
Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13:823–35PubMedCrossRef
8.
Rosai J. (ed) Large bowel. In: Rosai and Ackerman’s Surgical Pathology. 9th ed. Edinburgh: CV Mosby, 2004:776–855
9.
Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803–10PubMedCrossRef
10.
Doger FK, Meteoglu I, Tuncyurek P, Okyay P, Cevikel H. Does the EGFR and VEGF expression predict the prognosis in colonic cancer? Eur Surg Res 2006; 38:540–4PubMedCrossRef
11.
Meropol NJ. Epidermal growth factor receptor inhibitors in colorectal cancer: it’s time to get back on target. J Clin Oncol 2005; 23:1791–3PubMedCrossRef
Metadata
Title
Epidermal Growth Factor Receptor and Prognosis in Colon Cancer: A Crack in the Wall?
Authors
Gerardo Ferrara, MD
Natalia Palombi, PhD
Arturo Di Blasi, MD
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9375-y

Other articles of this Issue 7/2007

Annals of Surgical Oncology 7/2007 Go to the issue

Breast Oncology

Pathological and Biological Differences Between Screen-Detected and Interval Ductal Carcinoma in situ of the Breast

Medical Oncology

A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin

Gastrointestinal Oncology

Comparison of Functional and Surgical Outcomes of Laparoscopic-Assisted Colonic J-Pouch Versus Straight Reconstruction After Total Mesorectal Excision for Lower Rectal Cancer

Gynecologic Oncology

The Definition of Optimal Inguinal Femoral Nodal Dissection in the Management of Vulva Squamous Cell Carcinoma

Gastrointestinal Oncology

Oncologic Results of Laparoscopic D3 Lymphadenectomy for Male Sigmoid and Upper Rectal Cancer with Clinically Positive Lymph Nodes

Endocrine

The Role of Intra-Arterial Calcium Stimulation Test with Hepatic Venous Sampling (IACS) in the Management of Occult Insulinomas